Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 2/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GALK1 | P51570 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670129 | 0.88 | MEN1 (0.40) | SLC22A12GCGRCOMTFTOMEN1 | |
| SCHEMBL32670060 | 0.79 | COMT (0.43) | SLC22A12GCGRCOMTFTOALDH1A1 | |
| SCHEMBL32670033 | 0.78 | COMT (0.41) | COMTFTOMEN1ALDH1A1POLB | |
| SCHEMBL32669970 | 0.78 | MEN1 (0.39) | COMTFTOMEN1ALDH1A1POLB | |
| SCHEMBL32669819 | 0.78 | FTO (0.60) | COMTFTOMEN1ALDH1A1MAPT | |
| SCHEMBL32669922 | 0.78 | MEN1 (0.38) | COMTFTOMEN1ALDH1A1POLB | |
| SCHEMBL32669743 | 0.77 | MEN1 (0.39) | COMTFTOMEN1ALDH1A1POLB | |
| SCHEMBL32669777 | 0.76 | SLC22A12 (0.43) | SLC22A12GCGRCOMTFTOMEN1 | |
| SCHEMBL32670105 | 0.74 | ALDH1A1 (0.37) | SLC22A12COMTFTOMEN1ALDH1A1 | |
| SCHEMBL32669956 | 0.73 | COMT (0.55) | SLC22A12GCGRCOMTFTOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | SLC22A12 1753/4885GCGR 77/4885COMT 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.